Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer's disease
INTRODUCTION: Alzheimer's disease (AD) is one of the most common neurodegenerative disorders among the older population. Sleep disruption and circadian rhythm disorders often develop in AD patients, and many experience sleeping difficulties requiring pharmacological and non-pharmacological interventions.
AREAS COVERED: This review appraised the evidence from clinical studies on various pharmacological and non-pharmacological therapies for sleep disturbances in AD patients and proposed an algorithm to manage sleep disturbances in this population of patients.
EXPERT OPINION: Non-pharmacological interventions are generally preferred as the first-line approach to improve sleep-related symptoms in AD due to their favorable safety profile. However, when non-pharmacological interventions alone are insufficient, a range of pharmacological agents can be considered. Trazodone and melatonin are commonly used as adjunctive therapies, while Z-drugs including zopiclone and zolpidem are specifically employed to treat insomnia in patients with late-onset AD. Furthermore, a newer class of agents known as dual orexin receptor antagonists has emerged and gained approval for improving sleep onset and maintenance in AD patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Expert review of neurotherapeutics - 23(2023), 6 vom: 01. Juni, Seite 501-514 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Javed, Binish [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer’s disease |
|---|
| Anmerkungen: |
Date Completed 07.06.2023 Date Revised 08.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737175.2023.2214316 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357691830 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357691830 | ||
| 003 | DE-627 | ||
| 005 | 20231226073135.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737175.2023.2214316 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1192.xml |
| 035 | |a (DE-627)NLM357691830 | ||
| 035 | |a (NLM)37267149 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Javed, Binish |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological and non-pharmacological treatment options for sleep disturbances in Alzheimer's disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.06.2023 | ||
| 500 | |a Date Revised 08.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Alzheimer's disease (AD) is one of the most common neurodegenerative disorders among the older population. Sleep disruption and circadian rhythm disorders often develop in AD patients, and many experience sleeping difficulties requiring pharmacological and non-pharmacological interventions | ||
| 520 | |a AREAS COVERED: This review appraised the evidence from clinical studies on various pharmacological and non-pharmacological therapies for sleep disturbances in AD patients and proposed an algorithm to manage sleep disturbances in this population of patients | ||
| 520 | |a EXPERT OPINION: Non-pharmacological interventions are generally preferred as the first-line approach to improve sleep-related symptoms in AD due to their favorable safety profile. However, when non-pharmacological interventions alone are insufficient, a range of pharmacological agents can be considered. Trazodone and melatonin are commonly used as adjunctive therapies, while Z-drugs including zopiclone and zolpidem are specifically employed to treat insomnia in patients with late-onset AD. Furthermore, a newer class of agents known as dual orexin receptor antagonists has emerged and gained approval for improving sleep onset and maintenance in AD patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Alzheimer’s disease | |
| 650 | 4 | |a cholinesterase inhibitors | |
| 650 | 4 | |a dementia | |
| 650 | 4 | |a melatonin levels | |
| 650 | 4 | |a sleep disorders | |
| 650 | 4 | |a tau proteins | |
| 700 | 1 | |a Javed, Amaan |e verfasserin |4 aut | |
| 700 | 1 | |a Kow, Chia Siang |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Syed Shahzad |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of neurotherapeutics |d 2001 |g 23(2023), 6 vom: 01. Juni, Seite 501-514 |w (DE-627)NLM15501806X |x 1744-8360 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:6 |g day:01 |g month:06 |g pages:501-514 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737175.2023.2214316 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 6 |b 01 |c 06 |h 501-514 | ||